Archive - 2015

10 December 2015 - Press Releases

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK, 10 December 2015 – Karus Therapeutics (‘Karus’), a leader in the development of innovative medicines with breakthrough potential in the treatment of hematological cancers and solid tumor immunotherapy, today announced that it has entered into a strategic pre-clinical and clinical collaboration with The University of Texas MD Anderson Cancer Center. The collaboration will include both of Karus’s lead cancer candidates, KA2237 and KA2507.

 

Read more

07 December 2015 - Press Releases

Karus Therapeutics presenting at the 4th Annual Cancer BioPartnering & Investment Forum

Oxford, UK, 7 December 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the 4thAnnual Cancer BioPartnering & Investment Forum, New York, USA on the 24th February 2016.

Read more

Abstracts

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Alexander A., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J.
57th ASH Annual Meeting and Exposition, Orlando, 5 December 2015, Poster I, Publication # 2052. Blood December 3, 2015, 126 (23).

Abstracts

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J.
EORTC-NCI-EMA-AACR Conference on Innovation and Biomarkers in Cancer Drug Development, Brussels, December 4, 2015, Abst IBCD15-01.

30 November 2015 - Press Releases

Karus Therapeutics presenting at the 8th Annual Biotech Showcase 2016

Oxford, UK, 30th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the Biotech Showcase, San Francisco, USA, 11th-13th January 2016.

Read more

26 November 2015 - Press Releases

Karus Therapeutics presenting at the 57th ASH Annual Meeting

Oxford, UK, 26th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the 57th ASH Annual Meeting, Orlando, USA.

Read more

Abstracts

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 7, 2015, Abstract B115.

Abstracts

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy.
Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, November 6, 2015, Abstract A68.

02 November 2015 - Press Releases

Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development, Brussels, Belgium.  The conference will take place in 2016.

Read more

04 October 2015 - Press Releases

Karus Therapeutics presenting AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oxford, UK, 4 October 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving two poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 5-9 November 2015, Boston, USA

Read more

Abstracts

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque,K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster B009, Session B.

Abstracts

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster B008, Session B.

Abstracts

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers.
Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3639.

Abstracts

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors.
Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3662.

15 April 2015 - Press Releases

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer and inflammatory disease, has announced that it will be presenting at Sachs Immuno-oncology: BD&L and Investment Forum, Chicago, USA, 29th May 2015.

Read more

18 March 2015 - Press Releases

Karus Therapeutics presenting at AACR Annual Meeting 2015

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in Philadelphia, 18–22 April 2015.

Read more

18 March 2015 - Press Releases

Karus Therapeutics presenting at BioTrinity 2015

Simon Kerry, CEO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting at BioTrinity 2015, 11-13 May 2015 in Oxford, UK.

Read more